ديمة حسين - دكتوراة


Scientific Profile:

Dr> Deema Hussein Dr. Deema has completed her BSc in Genetics and Biochemistry at the University of Wales, UK, in conjunction with a Windsor Fellowship Management Training Programme in 1999. In 2003 she completed a PhD. in Cancer Cell Biology at the University of Manchester, UK, where she studies cell division in tumour cell lines. Her first postdoc training was at the Paterson Institute for Cancer Research in Manchester studying the effect of hypoxia on the drug response of neuroblastoma cell lines to clinically relevant therapeutic reagents followed by a research fellow training on pre-clinical evaluation of novel therapeutic reagents in paediatric tumours. Dr. Deema continued her training in 2006 as senior research fellow at the University of Nottingham, UK, studying the role Cancer Stem Cells (CSCs) have in drug resistance of paediatric brain tumours. In 2009 she joined the Medical College in the University of Hail, Saudi Arabia, working as assistant professor in Medical Genetics and undertaking the role of the medical college’s Academic Supervisor. She has several papers published in international journals including Journal of Cell Science and Molecular Cancer Therapeutics, has presented her work in several international conferences including American Association for Cancer Research, and was awarded grants from different bodies including the British National Institute for Health Research (NIHR). She is currently a member of the British Biotechnology and Biological Sciences Research Council.

Publications:

1. Hussein D, Punjaruk W, Storer L, Shaw L, Ottoman R, Peet A, Miller S, Bandopadhya G, Heath R, Kumari R, Bowman K, Rahman R, Jones G, Watson S, Lowe J, Kerr I, Grundy R, Coyle B. Cancer stem cells in 7 new pediatric brain tumor cell lines: detailed characterisation and investigation of etoposide drug resistance. Neuro Oncol. 2011, Jan;13(1):70-83.

2. Hussein D, Holt SV, Brookes KE, Klymenko T, Adamski JK, Hogg A, Estlin EJ, Ward T, Dive C, Makin GW. Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours. Br J Cancer. 2009, Jul 7;101(1):55-63.

3. Hussein D, Estlin EJ, Dive C, Makin GW. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther. 2006, Sep;5(9):2241-50.

4. Holt SV, Vergnolle MAS, Hussein D, Wozniak MJ, Allan VJ and Taylor SS. Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint. J Cell Sci 2005, 118 4889-4900.

5. Johnson VL, Scott MI, Holt SV, Hussein D, Taylor SS. Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression. J Cell Sci. 2004, 117:1577-89.

6. Hussein D, Taylor SS. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci. 2002, 115: 3403-14.

7. Taylor SS, Hussein D, Wang Y, Elderkin S, and Morrow CJ. Kinetochore localisation and phosphorylation of the mitotic checkpoint components Bub1 and BubR1 are differentially regulated by spindle events in human cells. J. Cell Sci. 2001, 114: 4385-4395.